|
Orthologous residues
|
|
ALK (human): Y1604‑p, ALK (mouse): ‑
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, mutation of modification site, phospho-antibody, phosphopeptide mapping, western blotting
|
|
Disease tissue studied:
lymphoma, anaplastic large cell lymphoma, non-Hodgkin's lymphoma
|
|
Relevant cell lines - cell types - tissues:
BaF3 ('B lymphocyte, precursor'), Karpas-299 (T lymphocyte), Rat1 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Comments:
Transfection of the constitutively active tyrosine kinase NPM-ALK into Ba/F3 and Rat-1 cells leads to a transformed phenotype.
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
cell cycle regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
PLCG1 (mouse)
|
SH2
|
Induces
|
activation
|
|
co-immunoprecipitation
|
|
|
Comments:
The complex formation leads to the tyrosine phosphorylation and activation of PLC-gamma.
|
